Liminatus Pharma Class A (LIMN)
Develops oncology antibodies and autologous CAR-T candidates through a license- and partner-dependent model.
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that its board of directors has adopted resolutions approving a reverse stock split of its common stock, par value $0.0001 per share (“Common Stock”), at a ratio of 1-for-50 (the “Reverse Stock Split”), which was approved by stockholders at the Company's 2026 Annual Meeting of Stockholders held on August 3, 2026.
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
FULLERTON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has amended and restated the previously announced definitive merger agreement with InnocsAI LLC ("InnocsAI"), an oncology biotechnology company focused on next-generation cell therapy technologies.
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
FULLERTON, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that it has entered into a warrant exercise agreement with existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 10,344,000 shares of common stock of the Company (the “Existing Warrants”).
Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session
Liminatus Pharma Inc. shares soared in after-hours trading after the company announced a merger agreement with InnocsAI LLC.
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage immuno-oncology company developing next-generation CD47-blockade therapies, today announced the pricing of its best-efforts public offering of 13,813,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per pre-funded warrant) and accompanying warrants. The warrants will have an exercise price of $0.29 per share, will be exercisable immediately upon issuance and will expire on the fifth anniversary of the original issuance date. The closing of the offering is expected to occur on or about February 18, 2026, subject to the satisfaction of customary closing conditions. Gross proceeds, before deducting placement agent fees and other estimated offering expenses, are expected to be approximately $4.0 million. The potential additional gross proceeds to the Company from the exercise of the warrants, if fully exercised on a cash basis, would be approximately $6.0 million. No assurance can be given that any warrants will be exercised.
Comparing Liminatus Pharma (NASDAQ:LIMN) & Inhibikase Therapeutics (NASDAQ:IKT)
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations. Valuation and Earnings This table compares Liminatus
Liminatus Pharma (NASDAQ:LIMN) vs. Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Contrast
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation. Analyst Recommendations This is a breakdown of
Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Survey
Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership. Profitability This table compares Inhibikase Therapeutics and
Analyzing Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT)
Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings. Valuation and Earnings This table compares Inhibikase
Liminatus Pharma (NASDAQ:LIMN) versus Prime Medicine (NASDAQ:PRME) Head to Head Comparison
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability. Profitability This table compares Liminatus Pharma and
Head to Head Analysis: Liminatus Pharma (NASDAQ:LIMN) versus Vor Biopharma (NASDAQ:VOR)
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Vor Biopharma (NASDAQ: VOR - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation. Institutional and Insider Ownership 97.3% of Vor
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment management firm, for a USD 30,000,000 equity financing via an earn-out mechanism to support Liminatus's research and development of advanced immunotherapy assets.
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backed financing paths Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backed financing paths